相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pro-death signaling of cytoprotective heat shock factor 1: upregulation of NOXA leading to apoptosis in heat-sensitive cells
Patryk Janus et al.
CELL DEATH AND DIFFERENTIATION (2020)
Spliced XBP1 Levels Determine Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitor Bortezomib Independent of the Unfolded Protein Response Mediator GRP78
Bojana Borjan et al.
FRONTIERS IN ONCOLOGY (2020)
Identification of a highly lethal V3+TP53+ subset in ALK+ lung adenocarcinoma
P. Christopoulos et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC
Youjin Kim et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study
D. Ross Camidge et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
Meletios A. Dimopoulos et al.
LANCET (2019)
Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival
Petros Christopoulos et al.
CANCERS (2019)
The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base
Xiao-Dong Jiao et al.
LUNG CANCER (2018)
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
A. Kron et al.
ANNALS OF ONCOLOGY (2018)
Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC)
Catherine Labbe et al.
LUNG CANCER (2017)
Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer
Tatsuya Yoshida et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Andras Kotschy et al.
NATURE (2016)
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
P. Moreau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
Justin F. Gainor et al.
CANCER DISCOVERY (2016)
The role of DNA damage responses in p53 biology
Daniel Speidel
ARCHIVES OF TOXICOLOGY (2015)
In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line
Shigeki Nanjo et al.
CANCER SCIENCE (2015)
Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials
Zebo Huang et al.
FUTURE ONCOLOGY (2014)
Noxa and cancer therapy Tuning up the mitochondrial death machinery in response to chemotherapy
Marie-Christine Albert et al.
MOLECULAR & CELLULAR ONCOLOGY (2014)
BH3-only proteins Noxa, Bik, Bmf, and Bid activate Bax and Bak indirectly when studied in yeast model
Gabriela Gerecova et al.
FEMS YEAST RESEARCH (2013)
BAK and NOXA Are Critical Determinants of Mitochondrial Apoptosis Induced by Bortezomib in Mesothelioma
Sara Busacca et al.
PLOS ONE (2013)
Hypoxia, Mn-SOD and H2O2 regulate p53 reactivation and PRIMA-1 toxicity irrespective of p53 status in human breast cancer cells
Manuel Rieber et al.
BIOCHEMICAL PHARMACOLOGY (2012)
CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
Hiroshi Sakamoto et al.
CANCER CELL (2011)
SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis
D. Li et al.
CELL DEATH AND DIFFERENTIATION (2011)
TP53 Mutations in Korean Patients with Non-small Cell Lung Cancer
Eung Bae Lee et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2010)
Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells
Teru Hideshima et al.
BLOOD (2009)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3
Ronald Pak Cheung Wong et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer
Michael P. Fanucchi et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells
JZ Qin et al.
CANCER RESEARCH (2005)
Proteasome inhibitor PS-341 induces a apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells
A Fribley et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
分享论文
